Nurix Therapeutics, Inc.: Rubric Capital Management LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Rubric Capital Management LP amended its Schedule 13G filing with the SEC regarding its stake in Nurix Therapeutics, Inc., per accession number 0001104659-26-128335. The amendment updates the investment firm's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding more than 5% of a company's shares and are typically amended when holdings shift. The specific revised share count and percentage were not detailed in the filing summary. Investors will watch for further 13G or 13D filings to gauge whether Rubric's position is increasing or being trimmed.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Nurix Therapeutics, Inc., Rubric Capital Management LP